EAACI Congress 2025

Back
13 - 16 June 2025 Glasgow, United Kingdom

Tezepelumab reduces OCS use and improves sino-nasal symptoms in OCS-dependent patients with severe asthma and comorbid chronic rhinosinusitis (overall and with nasal polyps): results from the phase 3b WAYFINDER study

Friday 13 Jun, 13:27 PM - 13:39 PM Glasgow, United Kingdom